Skip to main content

Health condition · Clinically reviewed

Leiomyosarcoma, a rare smooth-muscle cancer, managed by a specialist sarcoma team.

LMS is uncommon and can be difficult to tell apart from benign fibroids before surgery. Careful diagnosis and a specialist sarcoma pathway give the clearest picture.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, ESMO and specialist sarcoma-society sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including molecular profiling, trabectedin and pazopanib for advanced disease.

Key facts

Leiomyosarcoma at a glance.

The essentials, in plain English. What it is, where it starts, and how it is treated in the UK today.

  • What it is

    A malignant tumour of smooth muscle origin, arising wherever smooth muscle exists - most often the uterus, retroperitoneum, gut or blood vessels.

  • Common sites

    Uterine leiomyosarcoma is the most frequent form (see /conditions/gynaecological-cancers/), followed by retroperitoneal, gastrointestinal, cutaneous and vascular disease.

  • Not the same as fibroids

    Benign leiomyoma (fibroids, see /conditions/fibroids/) is far more common and can be very difficult to distinguish from LMS before surgery.

  • Grey-zone diagnosis

    STUMP - smooth muscle tumour of uncertain malignant potential - sits between benign and malignant and needs specialist follow-up.

  • Cornerstone of care

    Wide local excision with clear margins is the mainstay, with hysterectomy for uterine disease and selective radiotherapy or chemotherapy around it.

  • Where it is managed

    Specialist commissioned UK sarcoma centres such as the Royal Marsden and the Royal Orthopaedic Hospital, working through a dedicated sarcoma MDT.

Why this guide matters

A rare cancer that deserves a specialist pathway.

Leiomyosarcoma is easy to mistake for something more common, and the stakes of getting the diagnosis right are high. The three points below shape the whole plan.

  • It can hide behind fibroids

    Preoperative imaging cannot always tell leiomyosarcoma apart from benign leiomyoma, so unexpected diagnoses do occur.

  • Surgery is the biggest factor

    Complete wide local excision with clear margins, done without morcellation, is the single most important step in treatment.

  • Advanced disease has real options

    Doxorubicin, trabectedin and pazopanib give a structured ladder of systemic therapy for metastatic disease.

How the diagnosis is made

From first mass to a specialist plan.

The steps a UK GP, gynaecologist or sarcoma team will normally follow, so you know what to expect and why.

  1. 01

    Assessing

    History and red flags

    A growing mass, pain, weight loss and, in uterine disease, abnormal bleeding or a rapidly enlarging pelvic mass.

  2. 02

    Assessing

    Examination and site review

    Site-specific assessment - abdominal or pelvic mass, cutaneous nodule, or vascular signs depending on where the tumour sits.

  3. 03

    Assessing

    MRI of the primary site

    MRI (see /treatments/private-mri-scan/) characterises the mass, its margins and relationship to surrounding structures.

  4. 04

    Confirming

    CT chest, abdomen and pelvis

    Staging CT looks for pulmonary and other metastatic spread, essential before any definitive treatment plan.

  5. 05

    Confirming

    Core biopsy, not morcellation

    A core biopsy is strongly preferred over morcellation, which risks disseminating tumour cells through the abdomen or pelvis.

  6. 06

    Confirming

    Specialist sarcoma histopathology

    Immunohistochemistry for desmin and smooth muscle actin, read by specialist commissioned sarcoma pathology, confirms the diagnosis and grade.

  7. 07

    Planning

    Molecular profiling

    Specialist commissioned tumour molecular profiling (see /treatments/tumour-molecular-profiling/) informs prognosis and treatment choice.

  8. 08

    Planning

    Specialist sarcoma MDT

    Discussion at a specialist commissioned UK sarcoma centre agrees the surgical plan and any additional therapy.

Typical timeline: from first scan to a specialist sarcoma MDT plan in a few weeks.

Symptoms

What leiomyosarcoma tends to look like.

Presentation depends heavily on where the tumour starts. A mass, pain and weight loss are common threads, alongside site-specific features below.

  • A growing mass

    A palpable, often painless lump that has been slowly or, at times, rapidly enlarging over weeks to months.

  • Localised pain

    Deep, dull discomfort as the tumour presses on surrounding muscle, nerve or bowel.

  • Unintentional weight loss

    Weight loss and reduced appetite, particularly with larger retroperitoneal or metastatic disease.

  • Abnormal uterine bleeding

    Irregular or heavy bleeding with a pelvic mass - the classic presentation of uterine leiomyosarcoma.

  • Abdominal mass, often large

    Retroperitoneal disease is frequently large at diagnosis, since it can grow silently within the abdomen.

  • Bowel obstruction or bleeding

    Gastrointestinal leiomyosarcoma can present with obstruction, bleeding or a mass effect on the bowel.

  • A skin or vascular nodule

    Cutaneous leiomyosarcoma presents as a firm nodule; vascular disease, including the IVC, can present with venous obstruction.

  • Red flag: rapid growth or bleeding

    A rapidly enlarging mass, unexplained bleeding or new obstructive symptoms warrant urgent specialist sarcoma assessment.

Treatment

How leiomyosarcoma is treated in the UK.

Surgery first, selective radiotherapy around it, and a structured ladder of chemotherapy and targeted therapy for advanced or metastatic disease.

  • Wide local excision

    Surgical resection with clear margins is the mainstay of treatment, carried out at a specialist commissioned sarcoma surgery centre.

  • Hysterectomy for uterine LMS

    Total hysterectomy, avoiding morcellation, delivered by specialist commissioned gynae-oncology when the uterus is the primary site.

  • Adjuvant radiotherapy

    Selective, specialist commissioned radiotherapy after surgery for tumours at higher risk of local recurrence.

  • Doxorubicin-based chemotherapy

    The standard first-line chemotherapy backbone for advanced or metastatic disease, specialist commissioned.

  • Ifosfamide and gemcitabine/docetaxel

    Further chemotherapy combinations used in sequence for advanced disease, again specialist commissioned.

  • Trabectedin

    A targeted option with particular activity in leiomyosarcoma, used in specialist commissioned sarcoma units.

  • Pazopanib

    An oral targeted therapy for advanced soft-tissue sarcoma after chemotherapy (see /treatments/pazopanib-sarcoma-clinic/).

  • Palliative chemotherapy and support

    For metastatic disease, palliative chemotherapy alongside best supportive care and structured surveillance imaging, specialist commissioned throughout.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and international sarcoma-society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your sarcoma MDT knows your imaging, histology and molecular profile and can tell you which parts apply to you. If in doubt, ask.

  • NICE. Improving outcomes for people with sarcoma (CSG9) and related sarcoma guidance.

  • ESMO Clinical Practice Guidelines. Soft tissue and visceral sarcomas: diagnosis, treatment and follow-up.

  • Royal College of Obstetricians and Gynaecologists. Guidance on morcellation and unexpected uterine sarcoma.

  • Sarcoma UK. Patient information and support resources for people living with leiomyosarcoma.

Red flags

When leiomyosarcoma needs urgent attention.

Most leiomyosarcoma is managed on a planned specialist pathway. These are the situations that need faster escalation.

  • Rapidly enlarging mass

    A mass that grows noticeably over weeks, rather than months, needs urgent specialist sarcoma assessment rather than watchful waiting.

  • Suspected morcellation exposure

    If a presumed fibroid was morcellated and later found to be leiomyosarcoma, urgent specialist gynae-oncology review is needed because of the risk of tumour spread.

  • Heavy or unexplained uterine bleeding with a mass

    This combination should prompt urgent imaging and specialist gynaecological cancer referral, not routine fibroid management.

  • Bowel obstruction or major GI bleeding

    Gastrointestinal leiomyosarcoma causing obstruction or significant bleeding needs emergency surgical and oncology assessment.

  • Vascular obstruction, including IVC

    Leg swelling, abdominal distension or signs of venous obstruction from vascular leiomyosarcoma need urgent vascular and sarcoma review.

  • New breathlessness or chest symptoms

    Leiomyosarcoma commonly metastasises to the lungs; new respiratory symptoms warrant prompt staging imaging.

  • Pain unresponsive to simple analgesia

    Persistent, worsening pain from a known or suspected sarcoma should trigger an urgent oncology and palliative-care review.

  • Diagnostic uncertainty - STUMP

    A STUMP diagnosis needs structured, specialist follow-up rather than reassurance that it is definitively benign.

  • Symptoms on chemotherapy or targeted therapy

    Fever, breathlessness, severe fatigue or bleeding while on doxorubicin, trabectedin or pazopanib needs prompt oncology contact.

Living with it

A specialist condition, a long-term partnership.

Four things that make the biggest difference over the months and years after diagnosis: surveillance, treatment adherence, support and knowing when to seek a second opinion.

A quiet reminder

Consistency beats intensity, every time.

Steady scans, steady tablets and honest conversations with your sarcoma team keep the plan working.

  1. 01 Follow-up

    Keep to the surveillance schedule

    Regular CT and clinical review, typically every three to six months initially, catches recurrence while it remains treatable.

  2. 02 Adherence

    Stay consistent with oral therapy

    Pazopanib and other oral treatments work best taken every day. Report side effects to your team rather than stopping alone.

  3. 03 Support

    Use specialist sarcoma charities

    Sarcoma UK and related patient groups offer peer support and help navigating specialist commissioned care pathways.

  4. 04 Second opinion

    Ask about the sarcoma MDT

    Leiomyosarcoma is rare - a second opinion from a specialist commissioned sarcoma centre is a reasonable and welcomed request.

Frequently asked

Everything we get asked about leiomyosarcoma.

Quick answers on diagnosis, fibroids, STUMP, surgery and systemic treatment.

  • What is leiomyosarcoma?

    Leiomyosarcoma is a malignant tumour of smooth muscle origin. It can arise wherever smooth muscle is found, most often the uterus, retroperitoneum, gastrointestinal tract, blood vessels or skin, and it is managed as a soft-tissue sarcoma.

  • How is leiomyosarcoma different from a fibroid?

    Fibroids, or leiomyomas (see /conditions/fibroids/), are benign smooth muscle tumours and are far more common than leiomyosarcoma. The two can look very similar on imaging and are genuinely difficult to distinguish before surgery, which is why unexpected findings after fibroid surgery sometimes occur.

  • What is STUMP?

    STUMP stands for smooth muscle tumour of uncertain malignant potential. It describes a smooth muscle tumour that does not clearly meet the criteria for either benign leiomyoma or malignant leiomyosarcoma, and it needs structured specialist follow-up rather than a simple reassurance.

  • Why is core biopsy preferred over morcellation?

    Morcellation cuts a tumour into pieces to remove it through a smaller incision. If the mass turns out to be leiomyosarcoma, morcellation can disseminate tumour cells throughout the abdomen or pelvis, worsening the outlook. Core biopsy and, where malignancy is suspected, intact surgical removal are preferred.

  • What is the main treatment for leiomyosarcoma?

    Wide local excision with clear margins is the mainstay of treatment. For uterine disease this usually means hysterectomy, avoiding morcellation. Radiotherapy is used selectively, and chemotherapy with agents such as doxorubicin, ifosfamide, gemcitabine or docetaxel is used for higher-risk or advanced disease.

  • What options exist for advanced or metastatic leiomyosarcoma?

    Doxorubicin-based chemotherapy is typically first-line, with trabectedin and pazopanib used in later lines given their particular activity in leiomyosarcoma. For metastatic disease, treatment is aimed at controlling the cancer and maintaining quality of life alongside best supportive care.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.